Nasdaq: Climb Bio, Inc. Appoints Perrin Wilson, Ph.D. as Chief Business Officer Climb Bio appointed Dr.
Perrin Wilson as Chief Business Officer to strengthen its leadership in developing immune-mediated disease treatments. Climb Bio, Inc. has announced the appointment of Dr. Seeking Alpha: Generation Bio Reports Recent Business Highlights and First Quarter 2025 Financial Results Generation Bio Reports Recent Business Highlights and First Quarter 2025 Financial Results Nasdaq: YD Bio Limited Announces Closing of Business Combination and Listing on the Nasdaq Global Market YD Bio Limited Announces Closing of Business Combination and Listing on the Nasdaq Global Market SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Nura Bio, Inc.
bio for business, (Nura Bio), a clinical-stage, biopharmaceutical company developing neuroprotective, small molecule therapies for the treatment of ... Business Wire: Parallel Bio Secures $21 Million in Series A to Advance Human-First Drug Discovery CAMBRIDGE, Mass.--(BUSINESS WIRE)--Parallel Bio, a biotech company pioneering human-first drug discovery, today announced it has raised $21 million Series A funding, led by AIX Ventures. The round ... Seeking Alpha: Nuvation Bio Reports Third Quarter 2025 Financial Results and Provides Business Update Nuvation Bio Reports Third Quarter 2025 Financial Results and Provides Business Update
